Evidence map›Paper›PMID 30255971›Full record

SynthesisAnnals of neurology2018

Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia.

David Bergeron, Maria L Gorno-Tempini, Gil D Rabinovici, Miguel A Santos-Santos, William Seeley, Bruce L Miller, Yolande Pijnenburg, M Antoinette Keulen, Colin Groot, Bart N M van Berckel and 76 more

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Annals of neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Italian intersocietal recommendations for restructuring the diagnostic-therapeutic pathway for the implementation and appropriate use of anti-amyloid monoclonal antibodies in Alzheimer's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

86 authors.

David BergeronInterdisciplinary Clinic of Memory of the Child Jesus, Laval University, Quebec City, Quebec, Canada.
Maria L Gorno-TempiniMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA.
Gil D RabinoviciMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA.
Miguel A Santos-SantosMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA.
William SeeleyMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA.
Bruce L MillerMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA.
Yolande PijnenburgAlzheimer center Amsterdam, Amsterdam UMC, Amsterdam Neuroscience, VU University, Amsterdam, the Netherlands.
M Antoinette KeulenAlzheimer center Amsterdam, Amsterdam UMC, Amsterdam Neuroscience, VU University, Amsterdam, the Netherlands.
Colin GrootAlzheimer center Amsterdam, Amsterdam UMC, Amsterdam Neuroscience, VU University, Amsterdam, the Netherlands.
Bart N M van BerckelDepartment of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands.
Wiesje M van der FlierAlzheimer center Amsterdam, Amsterdam UMC, Amsterdam Neuroscience, VU University, Amsterdam, the Netherlands.
Philip ScheltensAlzheimer center Amsterdam, Amsterdam UMC, Amsterdam Neuroscience, VU University, Amsterdam, the Netherlands.
Jonathan D RohrerDementia Research Centre, UCL Institute of Neurology, University College London, London, United Kingdom.
Jason D WarrenDementia Research Centre, UCL Institute of Neurology, University College London, London, United Kingdom.
Jonathan M SchottDementia Research Centre, UCL Institute of Neurology, University College London, London, United Kingdom.
Nick C FoxDementia Research Centre, UCL Institute of Neurology, University College London, London, United Kingdom.
Raquel Sanchez-ValleAlzheimer's Disease and Other Cognitive Disorders Unit, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.
Oriol Grau-RiveraAlzheimer's Disease and Other Cognitive Disorders Unit, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.
Ellen GelpiAlzheimer's Disease and Other Cognitive Disorders Unit, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.
Harro SeelaarAlzheimer Center, Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Janne M PapmaAlzheimer Center, Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands.
John C van SwietenAlzheimer Center, Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands.
John R HodgesBrain and Mind Centre, School of Medical Sciences, University of Sydney, Sydney, New South Wales, Australia.
Cristian E LeytonFrontotemporal Dementia Unit, Department of Neurology, Massachusetts Alzheimer's Disease Research Center, Harvard Medical School, Boston, MA.
Olivier PiguetBrain and Mind Centre, School of Medical Sciences, University of Sydney, Sydney, New South Wales, Australia.
Emily J RogalskiNeurological Sciences, Rush University, Chicago, IL.
Marsel M MesulamCognitive Neurology and Alzheimer Disease Center, Northwestern University Medical School, Chicago, IL.
Lejla KoricDepartment of Neurology and Neuropsychology, La Timone Hospital, Marseille, France.
Nora KristensenDepartment of Neurology and Neuropsychology, La Timone Hospital, Marseille, France.
Jeéreémie ParienteUniversity of Toulouse, INSERM, Toulouse Neuroimaging Center, Toulouse, France.
Bradford DickersonFrontotemporal Dementia Unit, Department of Neurology, Massachusetts Alzheimer's Disease Research Center, Harvard Medical School, Boston, MA.
Ian R MackenzieDivision of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Ging-Yuek R HsiungDivision of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Serge BelliardDivision of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
David J IrwinDepartment of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, PA.
David A WolkDepartment of Neurology, University of Pennsylvania, Philadelphia, PA.
Murray GrossmanDepartment of Neurology, University of Pennsylvania, Philadelphia, PA.
Matthew JonesCerebral Function Unit, Greater Manchester Neurosciences Centre, Manchester, United Kingdom.
Jennifer HarrisSchool of Community-Based Medicine, University of Manchester, Manchester, United Kingdom.
David MannDivision of Neuroscience and Experimental Psychology, School of Biological Sciences, University of Manchester, Manchester, United Kingdom.
Julie S SnowdenSchool of Community-Based Medicine, University of Manchester, Manchester, United Kingdom.
Patricio Chrem-MendezCenter of Aging and Memory, Neurological Research Institute, Buenos Aires, Argentina.
Ismael L CalandriCenter of Aging and Memory, Neurological Research Institute, Buenos Aires, Argentina.
Alejandra A AmengualCenter of Aging and Memory, Neurological Research Institute, Buenos Aires, Argentina.
Carole Miguet-AlfonsiDepartment of Neurology, CHRU Besançon and Integrative and Clinical Neurosciences Laboratory, Regional Memory Center, University of Bourgogne Franche-Comté, Besançon, France.
Eloi MagninDepartment of Neurology, CHRU Besançon and Integrative and Clinical Neurosciences Laboratory, Regional Memory Center, University of Bourgogne Franche-Comté, Besançon, France.
Giuseppe MagnaniDepartment of Neurology, Vita Salute University and IRCCS San Raffaele Hospital, INSPE, Milan, Italy.
Roberto SantangeloDepartment of Neurology, Vita Salute University and IRCCS San Raffaele Hospital, INSPE, Milan, Italy.
Vincent DeramecourtUniversity of Lille Nord de France, INSERM U1171, DISTALZ, Lille, France.
Florence PasquierUniversity of Lille Nord de France, INSERM U1171, DISTALZ, Lille, France.
Niklas MattssonClinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.
Christer NilssonClinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.
Oskar HanssonClinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.
Julia KeithAnatomical Pathology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Mario MasellisDepartment of Medicine (Neurology), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Sandra E BlackDepartment of Medicine (Neurology), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Jordi A Matías-GuiuDepartment of Neurology and Nuclear Medicine, San Carlos Clinical Hospital, San Carlos Health Research Institute, Complutense University of Madrid, Madrid, Spain.
María-Nieves Cabrera-MartinDepartment of Neurology and Nuclear Medicine, San Carlos Clinical Hospital, San Carlos Health Research Institute, Complutense University of Madrid, Madrid, Spain.
Claire PaquetMemory Center, Department of Neurology, Lariboisière-Fernand-Widal Hospital, Paris, France.
Julien DumurgierMemory Center, Department of Neurology, Lariboisière-Fernand-Widal Hospital, Paris, France.
Marc TeichmannDepartment of Neurology, National Reference Center for PPA and rare dementias, Pitié Salpêtriére Hospital, AP-HP, Paris, France.
Marie SarazinFrederic Joliot Hospital Service, ERL 9218 CNRS, CEA, Orsay, Île-de-France, France.
Michel BottlaenderFrederic Joliot Hospital Service, ERL 9218 CNRS, CEA, Orsay, Île-de-France, France.
Bruno DuboisCenter for Cognitive and Behavioral Diseases, Pitié Salpêtrière University Hospital, Paris, France.
Christopher C RoweDepartment of Molecular Imaging and Therapy, Austin Health, Melbourne, Victoria, Australia.
Victor L VillemagneDepartment of Molecular Imaging and Therapy, Austin Health, Melbourne, Victoria, Australia.
Rik VandenbergheDepartment of Neurology, University Hospital Leuven, Leuven, Belgium.
Elias GranadilloDepartment of Neurology, University of California, Los Angeles, Los Angeles, CA.
Edmond TengNeurobehavior Service, Department of Neurology, University of California, Los Angeles, Los Angeles, CA.
Mario MendezNeurobehavior Unit, West Los Angeles VA Medical Center, Los Angeles, CA.
Philipp T MeyerDepartment of Nuclear Medicine, Faculty of Medicine, University Hospital of Freiburg, Freiburg, Germany.
Lars FringsDepartment of Nuclear Medicine, Faculty of Medicine, University Hospital of Freiburg, Freiburg, Germany.
Alberto LleóMemory Unit, Department of Neurology, Santa Cruz and Saint Paul Hospital, Barcelona, Spain.
Rafael BlesaMemory Unit, Department of Neurology, Santa Cruz and Saint Paul Hospital, Barcelona, Spain.
Juan ForteaMemory Unit, Department of Neurology, Santa Cruz and Saint Paul Hospital, Barcelona, Spain.
Sang Won SeoDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Janine Diehl-SchmidDepartment of Psychiatry and Psychotherapy, Technical University of Munich, Munich, Germany.
Timo GrimmerDepartment of Psychiatry and Psychotherapy, Technical University of Munich, Munich, Germany.
Kristian Steen FrederiksenDepartment of Neurology, Danish Dementia Research Center, Copenhagen, Denmark.
Pascual Sánchez-JuanNeurology Service, Marqués de Valdecilla University Hospital, Santander, Spain.
Gaël ChételatINSERM UMR-S U1237, University of Caen Normandy, Caen, France.
Willemijn JansenDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.
Rémi W BouchardInterdisciplinary Clinic of Memory of the Child Jesus, Laval University, Quebec City, Quebec, Canada.
Robert Jr LaforceInterdisciplinary Clinic of Memory of the Child Jesus, Laval University, Quebec City, Quebec, Canada.
Pieter Jelle VisserLlobregat Hospital, ACE Foundation, Catalan Institute of Applied Neurosciences, UIC Barcelona, Barcelona, Spain.
Rik OssenkoppeleAlzheimer center Amsterdam, Amsterdam UMC, Amsterdam Neuroscience, VU University, Amsterdam, the Netherlands.

Funding

TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
Transgenic Mouse Models of Tau PathologiesP01AG017586 · NIA · UNIVERSITY OF PENNSYLVANIA · PI LEE, VIRGINIA M · 2000 to 2021
$37.3M
UPenn ADCC Biomarker CoreP30AG010124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI XIE, SHARON XIANGWEN · 1991 to 2020
$35.1M
Neuropathology CoreP30AG013854 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BIGIO, EILEEN H. · 1996 to 2020
$28.9M
PrPSc SPECIFIC INTERACTION WITH NOVEL PrP-Fc FUSION PROTEINSP50AG023501 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MILLER, BRUCE L · 2004 to 2018
$27.1M
The Four Repeat Tauopathy Neuroimaging InitiativeR01AG038791 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2010 to 2020
$18.1M
Progressive Aphasia Cognition Anatomy and ProgressionR01NS050915 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARIA LUISA GORNO TEMPINI · 2004 to 2026
$11.0M
Language in Primary Progressive AphasiaR01DC008552 · NIDCD · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MESULAM, MAREK-MARSEL M · 2007 to 2021
$8.5M
Spreading Tau Pathology in Non-Amnestic Alzheimer's DiseaseR01AG054519 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jeffrey S Phillips · 2018 to 2026
$7.4M
Training - The Frontotemporal Lobar Degeneration Clinical Research ConsortiumU54NS092089 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2014 to 2018
$6.4M
Connectomic imaging in familial and sporadic frontotemporal degenerationU01AG052943 · NIA · UNIVERSITY OF PENNSYLVANIA · PI GORNO TEMPINI, MARIA LUISA, GROSSMAN, MURRAY · 2016 to 2019
$5.9M
Determinants of neurodegenerative decline in the aphasic variant of Alzheimer's diseaseR01AG056258 · NIA · UNIVERSITY OF CHICAGO · PI ROGALSKI, EMILY J · 2017 to 2022
$4.1M
Department of Health BRC149/NS/MHMedical Research Council MR/J009482/1Medical Research Council MR/M008525/1Medical Research Council MR/M023664/1NIA NIH HHS P01 AG017586NIA NIH HHS P01 AG019724NIA NIH HHS P30 AG010124NIA NIH HHS P30 AG013854NIA NIH HHS P50 AG023501NIA NIH HHS R01 AG038791NIA NIH HHS R01 AG045611NIA NIH HHS R01 AG054519NIA NIH HHS R01 AG056258NIA NIH HHS U01 AG052943NIDCD NIH HHS K24 DC015544NIDCD NIH HHS R01 DC008552NINDS NIH HHS R01 NS050915NINDS NIH HHS R01 NS075075NINDS NIH HHS R01 NS100440NINDS NIH HHS U54 NS092089
6 · The paper itself

Abstract

objectiveTo estimate the prevalence of amyloid positivity, defined by positron emission tomography (PET)/cerebrospinal fluid (CSF) biomarkers and/or neuropathological examination, in primary progressive aphasia (PPA) variants.

methodsWe conducted a meta-analysis with individual participant data from 1,251 patients diagnosed with PPA (including logopenic [lvPPA, n = 443], nonfluent [nfvPPA, n = 333], semantic [svPPA, n = 401], and mixed/unclassifiable [n = 74] variants of PPA) from 36 centers, with a measure of amyloid-β pathology (CSF [n = 600], PET [n = 366], and/or autopsy [n = 378]) available. The estimated prevalence of amyloid positivity according to PPA variant, age, and apolipoprotein E (ApoE) ε4 status was determined using generalized estimating equation models.

resultsAmyloid-β positivity was more prevalent in lvPPA (86%) than in nfvPPA (20%) or svPPA (16%; p < 0.001). Prevalence of amyloid-β positivity increased with age in nfvPPA (from 10% at age 50 years to 27% at age 80 years, p < 0.01) and svPPA (from 6% at age 50 years to 32% at age 80 years, p < 0.001), but not in lvPPA (p = 0.94). Across PPA variants, ApoE ε4 carriers were more often amyloid-β positive (58.0%) than noncarriers (35.0%, p < 0.001). Autopsy data revealed Alzheimer disease pathology as the most common pathologic diagnosis in lvPPA (76%), frontotemporal lobar degeneration-TDP-43 in svPPA (80%), and frontotemporal lobar degeneration-TDP-43/tau in nfvPPA (64%).

interpretationThis study shows that the current PPA classification system helps to predict underlying pathology across different cohorts and clinical settings, and suggests that age and ApoE genotype should be considered when interpreting amyloid-β biomarkers in PPA patients. Ann Neurol 2018;84:737-748.

Indexed as

Amyloid beta-PeptidesAgedAged, 80 and overAge FactorsAphasia, Primary ProgressiveApolipoproteins EBrainFemaleGenotypeHumansMaleMiddle AgedPrevalenceAmyloid beta-PeptidesApoE protein, humanApolipoproteins E

Identifiers

PMID30255971
PMCPMC6354051

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.